Track the 에이프릴바이오 stock price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 에이프릴바이오 has recorded 40 public disclosures. Market capitalisation: €552.1bn. The latest transaction was filed on 1 July 2026 (Sale). Among the most active insiders: 유한양행. Every trade is accessible without an account.
40
Insider Decl.
n/a
Thresholds
n/a
20 ops.
Buy Volume
n/a
13 ops.
Sell Volume
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 17,181 of 28,065 companies
45.1
score / 100
Value
32
Quality
59
FCF yld-0.5%
Earn yld-1.5%
EV/EBITDA·
ROE-11%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
April Bio is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative biopharmaceutical solutions.